Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Receivables came in at $43000.0 in Q1 2026, down 45.57% year-on-year from $79000.0 in Q1 2025, and up 16.22% quarter-over-quarter from $37000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Receivables history runs 5 years deep, the most recent figure standing at $43000.0 for Q1 2026.
- On a quarterly basis, Receivables fell 45.57% year-over-year to $43000.0 in Q1 2026; TTM through Mar 2026 was $43000.0, a 45.57% decrease from a year earlier, with the FY2025 full-year figure at $37000.0, down 50.67% from the prior year.
- Receivables grew to $43000.0 in Q1 2026 per CRVS's latest filing, from $37000.0 in the prior quarter.
- Across five years, Receivables topped out at $1.2 million in Q4 2022 and bottomed at $11000.0 in Q3 2023.
- The 5-year median for Receivables is $61000.0 (2023), against an average of $154416.7.
- Across the five-year window, Receivables slumped 95.58% in 2023 and soared 1172.73% in 2024, its largest moves.
- Year by year, Receivables stood at $1.2 million in 2022, then slumped by 95.58% to $52000.0 in 2023, then jumped by 44.23% to $75000.0 in 2024, then plunged by 50.67% to $37000.0 in 2025, then rose by 16.22% to $43000.0 in 2026.
- Per Business Quant, the three latest CRVS Receivables figures stand at $43000.0 (Q1 2026), $37000.0 (Q4 2025), and $32000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | 43,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | 37,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 86,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 52,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Sep 30, 2023 | 11,000.00 |
| Dec 31, 2022 | 1.18 Mn |